<DOC>
	<DOCNO>NCT01542918</DOCNO>
	<brief_summary>This Phase I study , mean goal see study treatment safe . The purpose study test safety Lenalidomide different dose level , test safety Lenalidomide alone combination Rituximab ( also know Rituxan® ) .</brief_summary>
	<brief_title>Lenalidomide Plus Rituximab Recurrent/Refractory CNS Intraocular Lymphoma</brief_title>
	<detailed_description>Rationale Proposed Study There evidence immunomodulatory drug lenalidomide stimulate immune effector natural killer ( NK ) cell , thus promote rituximab efficacy via ADCC . Because evidence synergy rituximab lenalidomide NHL , patient respond lenalidomide monotherapy receive combine intravenous plus intraventricular rituximab addition lenalidomide . To maximize delivery central nervous system ( CNS ) , investigator propose administer rituximab via intravenous intraventricular route . The rationale intraventricular administration rituximab demonstration approximately 0.1 % systemically administer rituximab penetrate cerebral spinal fluid ( CSF ) intraventricular administration rituximab feasible achieves high concentration associate anti-lymphoma activity . This study thus build upon two Phase 1 trial intraventricular rituximab conduct UCSF define safety intraventricular route administration ; study , however , first evaluate combination intraventricular plus intravenous treatment . The rationale intravenous administration rituximab recurrent CNS lymphoma blood-brain-barrier likely partially disrupt , particularly lymphoma-associated contrast enhancement detectable MRI , fact evidence activity rituximab administer intravenously , monotherapy ( Batchelor et al. , 2011 ) potentially combination chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Ability give write informed consent willingness comply requirement protocol Age eighteen year older Tumors must CD20+ prior pathologic analysis All prospective participant must Ommaya reservoir ( equivalent ventricular access device ) insert part standard clinical care prior initiation study treatment . No concurrent methotrexate , thiotepa , cytarabine , investigational agent Absolute neutrophil count ( ANC ) &gt; 1,500 ( growth factor permit ) Platelets &gt; 50,000 ( platelet transfusion allow ) Total bilirubin &lt; /= 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) &lt; /= 3 x ULN . Stable dose glucocorticoid pretherapy . If patient receive dexamethasone , dose dexamethasone increase 96 hour prior initiation therapy . Renal function assess calculated creatinine clearance . Patients must calculate creatinine clearance &gt; /= 60ml/min CockcroftGault formula 24 hour urine demonstrating CrCl &gt; /= 60ml/min . Females childbearing potential ( FCBPs ) † must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day within 24 hour prior receive lenalidomide Cycle 1 must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBPs must also agree ongoing pregnancy test 28 day receive last dose lenalidomide . Men must agree use latex condom sexual contact FCBP even successful vasectomy . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant aspirin may use warfarin low molecular weight heparin ) . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . Intraventricular chemotherapy radiation therapy within 4 day start treatment Intravenous rituximab within 30 day start treatment Persistent neurotoxicity intraventricular methotrexate , cytarabine , thiotepa Anticipated survival le 1 month Pregnant woman woman childbearing potential use effective method birth control . Known hypersensitivity thalidomide lenalidomide The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Contraindication aspirin . If unable take aspirin , contraindication warfarin low molecular weight heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>CNS</keyword>
	<keyword>Intraocular</keyword>
	<keyword>Lymphoma</keyword>
</DOC>